Articles from Waters Corporation

Waters Corporation (NYSEWAT) will hold its Q1 2023 financial results conference call live on Tuesday, May 9th 2023 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least May 23rd, 2023, at midnight eastern time.

MSACL Conference 2023--Waters Corporation (NYSEWAT) today unveiled its next generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications.

Waters™ Corporation (NYSEWAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company.

PITTCON 2023 – Waters Corporation (NYSEWAT) today introduced Alliance iS, the next-generation intelligent HPLC System, designed to reduce compliance risk by adding new levels of proactive error detection, troubleshooting and ease-of-use. When combined with Waters’ compliance-ready Empower Chromatography Software and eConnect™ HPLC Columns, the Alliance iS High Performance Liquid Chromatography (HPLC) System streamlines the task of making accurate and precise measurements by detecting and eliminating common errors by up to 40%.i In doing so, the Alliance iS HPLC System helps QC laboratories consistently meet quality, safety, compliance, and on-time product delivery goals.

PITTCON 2023 — Waters Corporation (NYSEWAT) today announced a new Battery Cycler Microcalorimeter Solution from its TA Instruments™ Division for high-resolution characterization of battery cells. The instrument and software combination enables non-destructive testing under real-world operating conditions and significantly reduces experiment time from months to weeks, while providing decisive insights for greater battery efficiency, safety, and stability.

Waters Corporation’s (NYSEWAT) companywide commitment to “leaving the world better than we found it” has earned it the number five ranking on the Barron’s 2023 100 Most Sustainable Companies U.S. list – its third consecutive year on the list, and its second time amongst the top ten.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., Waters’ President and Chief Executive Officer, will participate in a fireside chat at the Cowen Healthcare Conference on Monday, March 6th, 2023 at 9:50AM Eastern Time.

Waters Corporation (NYSEWAT) today announced its financial results for the fourth quarter and full-year 2022.

Waters Corporation (NYSEWAT) today announced it has entered into an agreement to acquire Wyatt Technology, a pioneer in innovative light scattering and field-flow fractionation instruments, software, accessories, and services, for $1.36 billion in cash, subject to certain adjustments. The transaction is expected to close in the second quarter of 2023, subject to regulatory approvals and other customary closing conditions.

Waters Corporation (NYSEWAT) today announced waters_connect™ System Monitoring, a new Software-as-a-Service (SaaS) application that enables laboratory managers and analysts to monitor the real-time status of any chromatography instruments, regardless of the manufacturer, running on Waters™ Empower™ Software.

Waters Corporation (NYSEWAT) will hold its Q4 2022 financial results conference call live on Wednesday, February 15th 2023 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 1st, 2023, at midnight eastern time.

Waters Corporation (NYSEWAT) announced awards and recognitions from multiple independent industry organizations throughout 2022, highlighting strength and momentum of the company’s product portfolio, its culture, and leadership. Waters received more than 20 awards during the year that affirm the company’s position as a leading analytical tools and software provider committed to solving problems that matter.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the J.P. Morgan Healthcare Conference on Monday, January 9th, 2023 at 4:30PM Pacific Standard Time / 7:30PM Eastern Standard Time.

Waters Corporation (NYSEWAT) announced it has been named to the Dow Jones Sustainability North America Index (DJSI North America) for the second consecutive year. The DJSI is informed by the S&P Global Corporate Sustainability Assessment (CSA), an annual evaluation of companies' sustainability practices.

Waters Corporation (NYSEWAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company.

Waters Corporation (NYSEWAT) today announced a new Per-and Polyfluoroalkyl Substances (PFAS) quantitation workflow enabled by enhancements to its waters_connect™ for quantitation software. Through a combination of Waters™ ultra-sensitive instrumentation, sample prep chemistries and software, the end-to-end workflow simplifies and automates the measurement of PFAS in food, soil, air, and water at parts-per-quadrillion levels that meet and exceed regulatory detection limits.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate at the Evercore ISI HealthconX Conference virtually with a fireside on Tuesday, November 29th, 2022 from 1:00-1:45PM Eastern Standard Time.

Waters Corporation (NYSEWAT) today released its 2022 Environmental, Social, and Governance (ESG) Report highlighting the company’s efforts for 2021 and the first half of 2022 to reduce its environmental footprint, develop a workforce that is more representative of the society we live in, and continue strong governance practices.

Waters Corporation (NYSEWAT) today announced its financial results for the third quarter of 2022.

Waters Corporation (NYSEWAT) today introduced Extraction+ Connected Device, a new software-controlled product for the Waters™ Andrew+™ Pipetting Robot that automates the preparation of biological, food, forensics and environmental samples by solid phase extraction (SPE). The Extraction+ Connected Device eliminates the need to manually pipette and extract samples with a hands-free, automated approach to SPE. It can save scientists up to four hours of bench time for each sample set and reduce the risk of user-to-user variability.ii

Waters Corporation (NYSEWAT) today announced a combined investment of up to €6 million with support from IDA Ireland to expand its operations in Drinagh, Wexford to fund research and development (R&D) of new clinical diagnostics products. The operational expansion at the Wexford facility will create new scientific jobs through 2024.

Waters Corporation (NYSEWAT) will hold its Q3 2022 financial results conference call live on Tuesday, November 1st 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least November 15th, 2022, at midnight eastern time.

Waters Corporation (NYSEWAT) today introduced new, innovative powder rheology tooling and software for its TA Instruments™ HR Rheometers allowing scientists to make preciseii, repeatable powder rheology measurements simpler and faster. Such measurements enable materials scientists to optimize the processing and end-use performance of powders used in batteries, pharmaceuticals, additive manufacturing, food, personal care products, and coatings.

Waters Corporation (NYSEWAT), a global leader in analytical instruments and software, today announced its newly built Precision Chemical Manufacturing Facility in Taunton, Mass. has achieved LEED (Leadership in Energy and Environmental Design) certification. The products manufactured at this facility are essential for thousands of laboratories that ensure the quality and safety of medicines, food and water for millions of people worldwide.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate at the Bank of America 2022 Global Healthcare Conference in London, with a fireside chat on Wednesday, September 14th, 2022 at 9:05AM BST (UTC+1) / 4:05AM ET.

Waters Corporation (NYSEWAT) today announced its financial results for the second quarter of 2022.

Waters Corporation (NYSEWAT) announced it is providing both technology and expertise to help advance plant-based protein science in collaboration with researchers of the Plant Protein Innovation Center (PPIC) at the University of Minnesota. Waters scientists will work with PPIC researchers to develop a workflow for measuring the amino acid content of plant-based proteins using a Waters ACQUITY™ Premier UPLC System. Waters is the first analytical instrument company to become a member of the PPIC, an industry-leading interdisciplinary research center dedicated to studying plant and alternative proteins.

Waters Corporation (NYSEWAT) will hold its Q2 2022 financial results conference call live on Tuesday, August 2nd 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least August 16th 2022 at midnight eastern time.

ASMS 2022 – Waters Corporation (NYSEWAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™ SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass spectrometer.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2022 Global Healthcare Conference in New York City on Wednesday, June 8th, 2022 at 4:30PM Eastern Standard Time.

Waters Corporation (NYSEWAT) and The University of Delaware announced the grand opening of Immerse™ Delaware, a new Waters innovation and research laboratory. As part of their multi-year research partnership announced in October 2021, the lab opening is the first step on a journey to collaborate with biopharma scientists both in industry and academia to advance industrial processes for making and characterizing biotherapeutics.

Waters Corporation (NYSEWAT) today announced its financial results for the first quarter of 2022.

Waters Corporation (NYSEWAT) announced today that it will host its 2022 Investor Day on Thursday, May 19, 2022, starting at 8:45 a.m. (ET) at the New York Stock Exchange, 11 Wall St, New York, NY 10005.

Waters Corporation (NYSEWAT) will webcast its Q1 2022 financial results conference call live on Tuesday, May 3rd 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least May 17th 2022 at midnight eastern time.

Waters Corporation (NYSEWAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.i

Waters Corporation (NYSEWAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on waters_connect™ allows scientists using the BioAccord™ LC-MS System to confirm the mass of biomolecules and impurities made by synthetic or recombinant processes nearly twice as fast as other commercially available options.i

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Cowen Healthcare Conference on Wednesday, March 9th, 2022 at 2:10PM Eastern Standard Time.

Waters Corporation (NYSEWAT) Amol Chaubal, SVP & Chief Financial Officer will participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24th at 3:30PM Eastern Time.

Waters Corporation (NYSEWAT) today announced it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass Spectrometry (CDMS) technology and services. Financial details of the transaction are not being disclosed.

Waters Corporation (NYSEWAT) today announced fourth quarter 2021 sales of $836 million, an increase of 6% as reported and 8% in constant currency, compared to sales of $787 million for the fourth quarter of 2020.

Waters Corporation (NYSEWAT) announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report, measuring corporate policies and practices related to LGBTQ+ workplace equality.

Waters Corporation (NYSEWAT) today announced the U.S. Food and Drug Administration’s (FDA) Office of Regulatory Affairs (ORA) has purchased Waters™ Empower™ Chromatography Data Software (CDS) and NuGenesis™ Laboratory Management Software (LMS), expanding its deployment of Waters’ software to support its medical products testing operations across its five field science laboratories.

Waters Corporation (NYSEWAT) will webcast its Q4 2021 financial results conference call live on Tuesday, February 1st 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least February 15th, 2022 at midnight eastern time.

Waters Corporation (NYSEWAT) today announced it is expanding its waters_connect™ informatics software platform to support customers analyzing food and environmental samples with Waters’ tandem quadrupole mass spectrometers. The new MS Quan™ application for waters_connect allows laboratories screening large numbers of samples, or those who may be quantifying hundreds of small molecule components and contaminants in a single run, a more efficient means of processing and reviewing data and identifying batch-to-batch variations.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the J.P. Morgan Healthcare Conference virtually on Monday, January 10th, 2022 at 8:15AM Eastern Standard Time.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the Evercore ISI 4th Annual HealthCONx Healthcare Conference virtually on Tuesday, November 30th, 2021 at 12:10PM Eastern Standard Time.

Waters Corporation (NYSEWAT) today released its 2021 Sustainability Report, highlighting companywide achievements such as reductions in environmental impacts, supply chain enhancements and diversity and inclusion initiatives. In addition, the report covers Waters’ COVID-19 response priorities that include ensuring the safety and well-being of its employees, helping to mitigate the public health crisis, and maintaining global business continuity.

Waters Corporation (NYSEWAT) today announced third quarter 2021 sales of $659 million, an 11% increase as reported, compared to sales of $594 million for the third quarter of 2020. Foreign currency translation benefited sales growth by less than 1% for the quarter.

Waters Corporation (NYSEWAT) and Sartorius (DAX: SRT:GR) announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development. Sartorius and Waters will partner to implement the BioAccord™ LC-MS System from Waters as a new bioprocess analyzer with data connectivity to Sartorius’ Ambr® multi-parallel bioreactor systems to deliver mass spectral information on drug substances, related analytes and cell culture media. This combination will greatly accelerate and improve the accuracy and speed of tasks from clone selection to bioprocess optimization.

Waters Corporation (NYSEWAT) and the University of Delaware today announced a five-year research partnership to develop new analytical solutions for bioprocessing and biomanufacturing. Key to this partnership is Immerse™ Delaware, an Innovation and Research Lab, (“Immerse Delaware”) set to open in early 2022 located at the University of Delaware Science, Technology and Advanced Research (STAR) campus. At Immerse Delaware, Waters will partner with students and faculty to identify and address the most significant challenges facing the biopharmaceutical industry.

Waters Corporation (NYSEWAT) will webcast its Q3 2021 financial results conference call live on Tuesday, November 2nd, 2021 at 8:00 a.m. eastern time. Interested investors can access the live webcast of the presentation on Waters’ investor relations website at https://ir.waters.com. A replay of the webcast will be available until November 16th, 2021 at midnight eastern time.

Waters Corporation (NYSEWAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM International, Inc., a leader in specialty coatings, sealants, building materials and related services.

Waters Corporation (NYSEWAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with MaxPeak™ High Performance Surface (HPS) technology. The integrated high-resolution LC-MS system simplifies multi-attribute monitoring of biotherapeutics by improving analyte recovery and assay-to-assay reproducibility so that regulated laboratories can get needed medicines to patients faster.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will present at the Bank of America Global Healthcare Conference 2021 virtually on Thursday, September 16th, 2021 at 3:55PM BST (UTC+1) / 10:55AM Eastern Time.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Morgan Stanley’s 19th Annual Global Healthcare on Tuesday, September 14th, 2021 at 8:45AM Eastern Standard Time.

Waters Corporation (NYSEWAT) today announced second quarter 2021 sales of $682 million, a 31% increase as reported, compared to sales of $520 million for the second quarter of 2020. Foreign currency translation benefited sales growth by approximately 4% for the quarter.

Waters Corporation (NYSEWAT) will webcast its Q2 2021 financial results conference call live on Tuesday August 3rd, 2021 at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters’ website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until August 10th, 2021 at midnight eastern time.

Waters Corporation (NYSEWAT) today introduced TRIOS AutoPilot software from its TA Instruments Division for its thermal analyzer product line. The software helps laboratory staff using TA’s thermal analyzers create routine and streamlined standard operating procedures (SOPs) up to 25% faster, and avoid transcription errors that can inhibit productivity and can lead to inconsistent thermal analysis measurements that are used to assess materials performance as well as batch-to-batch product quality.

Waters Corporation (NYSEWAT) today announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR). Among their new collaborative projects, Waters and BTI have started work on applying analytics that can rapidly identify and visualize complex molecules within glycomics and metabolomics data to help ensure overall safety, accuracy, and speed of biologics manufacturing.

Waters Corporation (NYSEWAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China.

Waters Corporation (NYSEWAT) today introduced the Waters™ Arc™ Premier System, the first liquid chromatography system optimized for chromatographic separations on 2.5 – 3.5 micron columns to also feature Waters’ novel MaxPeak™ High Performance Surface (HPS) technology. The new system complements Waters’ best-selling MaxPeak Premier Columns to virtually eliminate the surface interactions that occur between sample analytes and instrument and column hardware, saving laboratories time wasted on costly passivation and providing greater confidence in separations results.

Waters Corporation (NYSEWAT) today introduced the Waters™ SELECT SERIES™ MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources. Together, these technologies enable scientists to explore molecular structure and function through the precise identification and localization of individual molecules in samples, with a unique combination of speed, resolution, and mass accuracy.

Waters Corporation (NYSEWAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.

Waters Corporation founder James L. Waters, a legendary inventor and pioneer in liquid chromatography whose work spurred a multi-billion-dollar industry and helped advance numerous scientific breakthroughs, passed away peacefully on May 17th. He was 95 years old.

Waters Corporation (NYSEWAT) today announced first quarter 2021 sales of $609 million, a 31% increase as reported, compared to sales of $465 million for the first quarter of 2020. Foreign currency translation benefited sales growth by approximately 4% for the quarter.

Waters Corporation (NYSEWAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12th, 2021 at 2:00PM Eastern Standard Time.

Waters Corporation (NYSEWAT) continues its transformation program with the announcement of several planned leadership appointments and executive retirements.

Waters Corporation (NYSEWAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters™ BioAccord™ LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes™. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).

Waters Corporation (NYSEWAT) will webcast its Q1 2021 financial results conference call live on Wednesday, May 5th, 2021 at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters’ website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until May 12th, 2021 at midnight eastern time.